2022
Comprehensive molecular profiling of pancreatic ductal adenocarcinoma in FNA, biopsy, and resection specimens
Razzano D, Bouza SJ, Hernandez PV, Wang M, Robert ME, Walther Z, Cai G. Comprehensive molecular profiling of pancreatic ductal adenocarcinoma in FNA, biopsy, and resection specimens. Cancer Cytopathology 2022, 130: 726-734. PMID: 35511415, DOI: 10.1002/cncy.22589.Peer-Reviewed Original ResearchConceptsFine-needle aspirationFine-needle biopsyPancreatic ductal adenocarcinomaOncomine Comprehensive AssayResection specimensMolecular alterationsMolecular testingFNB samplesDuctal adenocarcinomaTherapeutic implicationsSuccess rateComprehensive molecular analysisComprehensive molecular testingComprehensive molecular profilingPotential therapeutic implicationsSimilar success ratesResection casesKRAS mutationsFNB specimensFNA materialFNA specimensAmplification analysisMolecular profilingFusion assessmentGene mutations
2017
A Long-Term Survivor of Metastatic Pancreatic Adenocarcinoma: Free of Recurrence 12 Years After Treatment of Oligometastatic Disease
Stahl JM, Walther Z, Chang BW, Hochster HS, Johung KL. A Long-Term Survivor of Metastatic Pancreatic Adenocarcinoma: Free of Recurrence 12 Years After Treatment of Oligometastatic Disease. Cureus 2017, 9: e1007. PMID: 28293485, PMCID: PMC5333949, DOI: 10.7759/cureus.1007.Peer-Reviewed Case Reports and Technical NotesPancreatic ductal adenocarcinomaOligometastatic pancreatic ductal adenocarcinomaMetastatic pancreatic ductal adenocarcinomaAdjuvant gemcitabineResectable pancreatic ductal adenocarcinomaAggressive local therapyRecurrence 12 yearsMultiple liver metastasesAggressive local treatmentMetastatic pancreatic adenocarcinomaLong-term survivorsIdentification of patientsMutations of KRASSmall lung nodulesTime of deathTumor protein p53Oligometastatic diseaseDistant progressionLiver metastasesMetastatic diseaseDisease recurrenceLocal therapyWhipple procedureComplete resolutionAnastomosis site